*SFG, spotted fever group; OR, odds ratio; CI, confidence interval.
aAdjusted for potential confounders within each exposure group; OR, odds ratio; CI, confidence interval.
‡ORs are calculated as follows: for different age groups, we calculated 2 ORs—OR1 = odds (<36 y)/odds (36 45 y), OR2 = odds (<36 y)/odds (>45 y); for different education groups, OR = odds (low)/odds (high); for different job groups, OR = odds (chicken keepers)/odds (duck keepers).
CI, confidence interval; GC, group-specific component; OR, odds ratio; SNP, single-nucleotide polymorphism; VDR, vitamin D receptor.
*HPV, human papillomavirus; OR, odds ratio; Ref, reference group.
The odds of having a more severe local adverse event was greater in the high dose than in the low dose groups (odds ratio (OR) = 6.8, 95% CI 1.7, 27.8, p = 0.008), and in the CPG groups compared to the non-CPG groups (OR = 23.6, 95% CI 2.9, 192.7, p = 0.003).
For binary outcome data, we considered full reporting to have occurred if the sample size was reported in each group together with either the number of participants with the event for each group or the odds ratio or relative risk with precise P value or a measure of precision or variability (confidence interval or standard error).
Thus, the chances of having no AI symptoms were significantly higher in the study group, as compared to the OASI control group (odds ratio [OR] 2.95; 95% confidence interval [CI] 1.2 to 7.4), but similar to the vaginal control group (OR 1.4; 95%CI 0.5 to 3.7).
On the basis of intention-to-treat analyses, no significant group differences were observed in percentage of patients opting for a direct BLM (14.6% for the RGCT group vs 9.2% for the control group; odds ratio (OR) 2.31; confidence interval (CI) 0.92 5.81; P=0.08) or for a delayed CPM (4.5% for the RGCT group vs 5.7% for the control group; OR 0.89; CI 0.27 2.90; P=0.27 2.90
Risk of early dislocation (within 90 days) was compared in the 2 groups and odds ratio (OR)—adjusted for possible confounders was calculated.
